Itama Ranoraya's Net Profit Grows 23 Percent to Rp65.5 Billion in 2025
PT Itama Ranoraya Tbk (IRRA), a distributor of medical equipment, recorded a net profit of Rp65.53 billion in 2025, representing a 23.03 percent year-on-year (yoy) increase compared to Rp53.26 billion in the same period the previous year.
The company’s net profit was bolstered by revenue amounting to Rp1.1 trillion in 2025, a 12.55 percent (yoy) growth from Rp977.49 billion in the corresponding period last year.
IRRA’s President Director, Heru Firdausi Syarif, stated in an official release in Jakarta on Wednesday that this achievement results from expansion strategies across various business lines, accompanied by efficient operational cost controls.
“The growth in 2025 serves as an indicator that the company’s fundamentals remain intact amid the dynamics of the healthcare industry,” said Heru.
He continued that the net profit increase, which outpaced revenue growth, reflects the company’s success in sharpening its strategic product portfolio and maintaining operational efficiency.
“We focus on providing health solutions relevant to current medical trends, thereby contributing to the company’s margins without neglecting the affordability aspect for national healthcare services,” Heru added.
By the end of 2025, Heru stated that the company had completed various strategic investments focused on strengthening distribution infrastructure, logistics systems, inventory management, and enhancing human resource capabilities.
These steps drove a 46.65 percent (yoy) growth in the company’s total assets to Rp2.43 trillion as of the end of 2025, reflecting a significant increase in operational capacity.
“Such expansion also broadens the company’s service reach, with the distribution network growing 18.5 percent (yoy) to 2,504 points across Indonesia,” Heru explained.
On a sectoral basis, he elaborated that the company’s performance was supported by contributions from key business segments, including In Vitro Diagnostics worth Rp693.48 billion and Sterile Medical Electronic Equipment worth Rp347.94 billion.
Additionally, the Non-Electronic Sterile Medical Equipment segment contributed Rp52.88 billion, while Other Health Products recorded Rp5.91 billion.
Heru noted that the achievements in each segment were influenced by high market demand and the company’s success in expanding its new business portfolio, which positively contributes to overall revenue.
He further stated that the investment strengthening in 2025 is a planned step to enhance logistics capacity, expand distribution networks, and significantly increase market share.
“We believe that bolstering these strategic capabilities is key to maintaining the wider and faster availability of medical equipment in the market. Moving forward, we will focus on increasing market penetration in potential regions and ensuring that every expansion stage provides stable contributions to the company’s long-term growth,” Heru concluded.